Amicus Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 114.26 | -100% | -13.83 | -100% |
| P/S |
|
5.42 | 4.1 | 32.14% |
|
|
| P/BV |
|
14.76 | 9.02 | 63.58% |
|
|
| P/FCF |
|
-98.28 | 44.54 | -320.67% |
|
|
| Ev/Ebitda |
|
105.28 | 17.72 | 494.13% |
|
|
| Ev/S |
|
5.86 | 4.4 | 32.97% |
|
|
| Ev/FCF |
|
-82.63 | 54.7 | -251.07% |
|
|
| E/P |
|
-0.0152 | 0.2136 | -107.11% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
2/10
|
5.56 | 21.49 | -74.11% | -27.35 | -120.34% |
| ROE |
|
-31.68 | -82.41 | -61.56% |
|
|
| ROA |
|
-7.18 | 6.75 | -206.35% |
|
|
| ROIC |
|
0 | 15.68 | -100% |
|
|
| ROS |
|
-10.62 | 10.29 | -203.22% |
|
|
| ROCE |
|
10.74 | 55.43 | -80.62% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
0/10
|
15.1 | 0.9571 | 1477.27% | 4.18 | +260.74% |
| Nеt Debt/Ebitda |
|
7.82 | 2.1 | 273.29% |
|
|
| Debt/Ratio |
|
0.5651 | 0.2655 | 112.88% |
|
|
| Debt/Equity |
|
14.4 | 4.81 | 199.37% |
|
|
| Debt/Net Income |
|
-7.91 | 35.64 | -122.19% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.31 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 6.35 | -100% | ||
| DSI |
|
0 | 0.7501 | -100% |
|
|
| Average dividend growth |
|
0 | -0.99 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.28 | -100% |
|
|
| Average percentage for payments |
|
0 | 77.77 | -100% |
|
|
| Difference from average difference in sector |
|
-1.31 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
102.49 | 214.83 | -52.29% | ||
| Growth impulse Ebitda in 5 years |
|
-112.63 | 253.48 | -144.43% | ||
| Growth impulse Net Income in 5 years |
|
-79.74 | 270.34 | -129.5% | ||
| Growth impulse FCF in 5 years |
|
-84.17 | 183.09 | -145.97% | ||
| Growth impulse EPS in 5 years |
|
-82.77 | 149.95 | -155.2% |
IP Score
1.81/10
